Managing Adverse Events Of Immune Checkpoint Inhibitors

Immune checkpoint inhibitors such as Ipilimumab, Nivolumab and Pembrolizumab have been approved by US FDA for variety of malignant neoplasms. They have significantly improved treatment but their use is also associated with unique immune-related adverse effects (irAEs). This article discusses about management of irAEs associated with these agents. Ipilimumab (anti CTLA-4) is currently approved by the US FDA for the treatment of metastatic melanoma.

Nivolumab and Pembrolizumab (PD-1 inhibitors) are both FDA approved for the treatment of metastatic melanoma and non–small cell lung cancer (NSCLC). Immune-Related Adverse Effects (irAEs) irAEs include dermatitis, enterocolitis, endocrinopathies, autoimmune hepatitis, pneumonitis, arthritis, sicca syndrome etc. Ipilimumab has a higher incidence of irAEs than Nivolumab and Pembrolizumab. The combination of nivolumab and ipilimumab has a higher…